Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dogwood Therapeutics, Inc. (DWTX)
USD1.44
+0.01 (+0.70%)
US NASDAQ Healthcare Biotechnology
Address
44 Milton Avenue 30009
Alpharetta, GA, US
Alpharetta, GA, US
CEO
Gregory Duncan
Website
dwtx.com
IPO
2020-12-17
CIK 1818844 ISIN US92829J2033
Description
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.44
+0.01 (+0.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
102.0K
Beta
1.71
Float Shares
1.35M
Free Float %
70.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.58% | +10.91% | +10.24% | -39.00% | -67.72% | -56.01% | -67.95% | -92.96% | -98.46% | -99.56% | -99.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.44
DCF (Unlevered)
0.69
-52.0%
DCF (Levered)
0.77
-46.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.35
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+65.5% ★ Q1'26: +98.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-40.8% Q1'26: -30.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+699.8% Q1'26: +2,227.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
128.77M
128.77M – 128.77M
|
18.73M
18.73M – 18.73M
-85.5% YoY
|
9.42M
9.42M – 9.42M
-49.7% YoY
|
57.40M
57.40M – 57.40M
+509.1% YoY
|
69.67M
69.67M – 69.67M
+21.4% YoY
|
| EBITDA |
-12.25M
|
-27.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-12.26M
|
-27.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-12.35M
est: -6.20M (-99.3%)
|
-34.26M
est: -54.40M (+37.0%)
|
-7.97M
-11.40M – -4.54M
+85.3% YoY
|
-10.27M
-15.92M – -4.62M
-28.8% YoY
|
-11.30M
-18.32M – -4.29M
-10.1% YoY
|
-1.03M
-1.03M – -1.03M
+90.9% YoY
|
9.17M
9.17M – 9.17M
+992.0% YoY
|
| SGA |
8.70M
|
6.10M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-12.52
est: -6.03 (-107.6%)
|
-4.32
est: -6.62 (+34.7%)
|
-0.97
-1.39 – -0.55
+85.3% YoY
|
-1.26
-1.94 – -0.56
-29.4% YoY
|
-1.33
-2.23 – -0.52
-5.6% YoY
|
-0.13
-0.13 – -0.13
+90.6% YoY
|
1.12
1.12 – 1.12
+992.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.00% | 37.8K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 218.3K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
577.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+577,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | Walsh Angela | Officer | A-Award | A | Stock Option (right to buy) | 82,500 | 2.86 | 236.0K | 82,500 | D | ↗ |
| 2026-03-05 | Grosswald Ralph | Officer | A-Award | A | Stock Option (right to buy) | 82,500 | 2.86 | 236.0K | 82,500 | D | ↗ |
| 2026-03-05 | Gendreau Roger Michael | Officer | A-Award | A | Stock Option (right to buy) | 82,500 | 2.86 | 236.0K | 82,500 | D | ↗ |
| 2026-03-05 | Duncan Gregory Scott | Director / Officer | A-Award | A | Stock Option (right to buy) | 330,000 | 2.86 | 943.8K | 330,000 | D | ↗ |
| 2025-12-04 | Walsh Angela | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 6.14 | 921.0K | 150,000 | D | ↗ |
| 2025-12-04 | Grosswald Ralph | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 6.14 | 921.0K | 150,000 | D | ↗ |
| 2025-12-04 | Gendreau Roger Michael | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 6.14 | 921.0K | 150,000 | D | ↗ |
| 2025-12-04 | Duncan Gregory Scott | Director / Officer | A-Award | A | Stock Option (right to buy) | 460,000 | 6.14 | 2.82M | 460,000 | D | ↗ |
| 2025-11-21 | Sealbond Ltd | Director / 10% Owner | C-Conversion | A | Common Stock | 21,610,950 | 0.00 | 2.2K | 21,822,333 | D | ↗ |
| 2025-06-27 | Whitley Richard James | Director | A-Award | A | Stock Option (right to buy) | 2,362 | 4.71 | 11.1K | 2,362 | D | ↗ |
| 2025-06-27 | Walsh Angela | Officer | A-Award | A | Stock Option (right to buy) | 12,075 | 4.71 | 56.9K | 12,075 | D | ↗ |
| 2025-06-27 | Thomas John C | Director | A-Award | A | Stock Option (right to buy) | 2,362 | 4.71 | 11.1K | 2,362 | D | ↗ |
| 2025-06-27 | Keefer David R | Director | A-Award | A | Stock Option (right to buy) | 2,362 | 4.71 | 11.1K | 2,362 | D | ↗ |
| 2025-06-27 | Grosswald Ralph | Officer | A-Award | A | Stock Option (right to buy) | 12,075 | 4.71 | 56.9K | 12,075 | D | ↗ |
| 2025-06-27 | Gendreau Roger Michael | Officer | A-Award | A | Stock Option (right to buy) | 12,075 | 4.71 | 56.9K | 12,075 | D | ↗ |
| 2025-06-27 | Duncan Gregory Scott | Director / Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 4.71 | 188.4K | 40,000 | D | ↗ |
| 2025-06-27 | De La Rosa Abel | Director | A-Award | A | Stock Option (right to buy) | 2,362 | 4.71 | 11.1K | 2,362 | D | ↗ |
| 2025-06-18 | Whitley Richard James | Director | A-Award | A | Stock Option (right to buy) | 210 | 4.80 | 1.0K | 420 | D | ↗ |
| 2025-06-18 | Thomas John C | Director | A-Award | A | Stock Option (right to buy) | 210 | 4.80 | 1.0K | 420 | D | ↗ |
| 2025-06-18 | Keefer David R | Director | A-Award | A | Stock Option (right to buy) | 210 | 4.80 | 1.0K | 420 | D | ↗ |
| 2025-06-18 | De La Rosa Abel | Director | A-Award | A | Stock Option (right to buy) | 210 | 4.80 | 1.0K | 420 | D | ↗ |
| 2025-03-12 | Conjoint Inc. | Director / 10% Owner | — | — | Series A-1 Preferred Stock | 2,842,638 | 0.00 | — | 0 | D | ↗ |
| 2025-03-12 | CK Life Sciences Intl (Holdings) Inc | Director / 10% Owner | A-Award | A | Series A-1 Preferred Stock | 284 | 0.00 | — | 284 | I | ↗ |
| 2024-10-07 | Yu Ying Choi Alan Abel | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-07 | Toh Kean Meng Melvin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-07 | Sealbond Ltd | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 211,383 | D | ↗ |
Executive team
Top executives
Shares Outstanding
1.91M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gregory Duncan | Chairman & Chief Executive Officer | 944.1K | male |
| R. Michael Gendreau | Chief Medical Officer | 551.1K | — |
| Angela Walsh | Chief Financial Officer, Secretary & Treasurer | 472.9K | female |
| Ralph D. Grosswald | Senior Vice President of Operations | 274.7K | male |
| William L. Pridgen | Founder & Member of Scientific Advisory Board | 16.3K | — |
| Carol Duffy | Chief Scientific Advisor | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DWTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
